Articles > Popular publications > PR Newswire press releases > October-December 2009 > Tuesday, November 3

Article: Cipher appoints Dr. William Claypool to Board of Directors.

Article from:
PR Newswire
Article date:
November 3, 2009
Copyright

Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, Nov. 3 /PRNewswire-FirstCall/ -- Cipher Pharmaceuticals Inc. (TSX: DND) today announced that Dr. William Claypool, M.D., has been appointed to its Board of Directors.

Since October 2008, Dr. Claypool has been a Senior Partner at Pennmark Associates, LLC, a pharmaceutical development consulting firm. Prior to that, Dr. Claypool served as President, CEO and Chairman of Phoenix Data Systems, Inc, from January 2001 until it was acquired by Bio-Imaging Technologies, Inc. in March 2008. From January 2001 until June 2001, he served as President and CEO of The GI Company. From 1991 to 2001 Dr. Claypool held a ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: Cipher Pharmaceuticals announces U.S. distribution ...
PR Newswire;  August 6, 2008 ;     700+ words ... ... Officer of Cipher Pharmaceuticals. "This ... ISOTRETINOIN's clinical development program while ... countries. About Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals is a drug ... through the clinical development and regulatory ...

Article: Cipher Pharmaceuticals receives approvable letter ...
PR Newswire;  April 27, 2007 ;     700+ words ... ... FirstCall/ -- Cipher Pharmaceuticals Inc. (TSX: DND ... Resolution process. About Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals is a drug development ... advance them through the clinical development and regulatory approval ...

Article: Begins Research on Cipher Pharmaceuticals Inc.
M2 Presswire;  January 17, 2006 ;     700+ words ... ... membership subscription. Cipher Pharmaceuticals Inc. is an innovative drug ... advance them through the clinical development and regulatory approval stages ... February of 2004. On Jan 13th, Cipher Pharmaceuticals Inc. was pleased to announce ...

Article: Cipher Pharmaceuticals enters into U.S. licensing ...
PR Newswire;  July 10, 2007 ;     700+ words ... ... FirstCall/ -- Cipher Pharmaceuticals Inc. (TSX: DND ... com/. About Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals is a drug development ... them through the clinical development and regulatory approval ...

Article: CML subsidiary Cipher Pharmaceuticals announces ...
Canadian Corporate News;  January 3, 2001 ;     700+ words ... ... healthcare company, today announced its recently created Cipher Pharmaceuticals subsidiary, has successfully completed a worldwide licensing ... cost approximately $4 to $6 million to complete the clinical development of this product. The Company plans to begin pivotal ...

Article: CML enters high growth drug development arena, -Launch of ...
Canadian Corporate News;  November 30, 2000 ;     700+ words ... ... an innovative Canadian drug development company named Cipher Pharmaceuticals Limited ("Cipher"). The new company will initially ... manufacturing capabilities. CML will support these ventures with clinical development support through its pharmaceutical research network ...

Article: FDA approval letter for CIP-Isotretinoin.(PIPELINE ...
Journal of Drugs in Dermatology;  July 1, 2007 ;     700+ words ...Cipher Pharmaceuticals, Inc recently announced that its New Drug Application for ... severe, recalcitrant cystic acne. The approval requires that Cipher Pharmaceuticals Inc submit additional clinical data as well as additional ...

Article: Market Regulation Services Halt Notice: Cipher ...
Canadian Corporate News;  February 22, 2006 ;     364 words ... ... 22, 2006 (CCNMatthews via COMTEX) -- The following issue(s) have been halted today: Company Cipher Pharmaceuticals Inc TSX Symbol DND Reason Pending news Halt Time (EST) 15:11 EST SOURCE: Market Regulation Services ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives